• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Drug company stops paying doctors for talks, endorsements

Article

GlaxoSmithKline changes its sales and marketing practices to put more focus on patients, CEO says.

As pressure mounts for physicians and drug manufacturers to be more transparent in their relationships with one another, one of the largest pharmaceutical companies has decided to stop paying doctors to promote their drugs.

GlaxoSmithKline, the world’s sixth-largest drug manufacturer, spent $15.4 million, per quarter, to doctors to promote products, in 2009, according to ProPublica. That number has dwindled to $2.4 million per quarter in 2012.

The company will also change its business model that ties compensation of sales representatives to prescriptions written. The changes will take place globally over the next 2 years.

The drug maker will continue to employ physicians for research, consulting, and market research.

“We believe that it is imperative that we continue to actively challenge our business model at every level to ensure we are responding to the needs of patients and meeting the wider expectations of society,” says Andrew Witty, CEO of GlaxoSmithKline.

Related Videos
Mike Bannon ©CSG Partners
Mike Bannon ©CSG Partners
Mike Bannon - ©CSG Partners
Mike Bannon - ©CSG Partners